- Trials with a EudraCT protocol (62)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
62 result(s) found for: Physical education.
Displaying page 1 of 4.
EudraCT Number: 2009-010227-62 | Sponsor Protocol Number: GE-067-005 | Start Date*: 2009-09-09 | |||||||||||
Sponsor Name:GE Healthcare Ltd and its Affiliates | |||||||||||||
Full Title: A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (F18) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzhei... | |||||||||||||
Medical condition: GE-067-005 will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer for predicting the conversion from amnestic Mild Cognitive Impairment to probable Alzheimer’s disease. Uptake... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002780-30 | Sponsor Protocol Number: 9515 | Start Date*: 2022-12-01 | |||||||||||
Sponsor Name:Aarhus University Hospital, The Research Clinic for Functional Disorders and Psychosomatics | |||||||||||||
Full Title: Efficacy of patient education and duloxetine, alone and in combination, for patients with multiorgan bodily distress syndrome: a partial-factorial randomized controlled trial (the EDULOX-trial) | |||||||||||||
Medical condition: Multiorgan Functional somatic disorders (FSD) / bodily disstress syndrome (BDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000809-71 | Sponsor Protocol Number: APPI2-PT-2019-01 | Start Date*: 2019-06-18 | |||||||||||
Sponsor Name:The Parker Institute, Bispebjerg and Frederiksberg Hospital, The Capital Region of Denmark | |||||||||||||
Full Title: Direct comparison of intra-articular saline injections with an education plus exercise program for treatment of knee osteoarthritis symptoms: A randomised, open label, controlled, evidence based trial | |||||||||||||
Medical condition: Knee osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010725-39 | Sponsor Protocol Number: 56493 | Start Date*: 2009-07-23 | |||||||||||
Sponsor Name:The University of Manchester [...] | |||||||||||||
Full Title: A randomised controlled trial to measure the effects and costs of a dental caries prevention regime for young children attending primary care dental services | |||||||||||||
Medical condition: Dental Caries | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010067-16 | Sponsor Protocol Number: CN156018 | Start Date*: 2009-07-08 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of BMS-708163 in the Treatment of Patients with Prodromal ... | |||||||||||||
Medical condition: ALZHEIMER DISEASE | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001927-74 | Sponsor Protocol Number: SysVac01-C60P2 (PA/2008/2883) | Start Date*: 2009-01-16 |
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||
Full Title: A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VES... | ||
Medical condition: "Healthy volunteers" In this project we will establish whether naturally induced mucosal CD25+ T regulatory activity in adults and adolescents modulates the mucosal immune response to systemic Me... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-006042-32 | Sponsor Protocol Number: GE-067-019 | Start Date*: 2012-09-12 | |||||||||||
Sponsor Name:GE Healthcare Ltd and its affiliates | |||||||||||||
Full Title: A Single-Arm Open-Label Multi-Center Study to Determine the Test-Retest Variability of PET Brain Imaging with Flutemetamol (18F) Injection. | |||||||||||||
Medical condition: Subjects with amnestic Mild Cognitive Impairment (aMCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002505-74 | Sponsor Protocol Number: CEP1538/3034/ES/MN | Start Date*: 2005-01-05 | |||||||||||
Sponsor Name:Cephalon Europe, A Division of Cephalon UK Limited | |||||||||||||
Full Title: A 6 month open-label, flexible-dosage study to assess the safety and effectiveness of PROVIGIL® (Modafinil) treatment in children and adolescents with excessive sleepiness associated with narcoleps... | |||||||||||||
Medical condition: Excessive sleepiness associated with Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FI (Completed) GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001041-20 | Sponsor Protocol Number: F001AM0222_1 | Start Date*: 2022-10-14 |
Sponsor Name:University Hospital Wuerzburg | ||
Full Title: Prednisolone and vitamin B1, B6, and B12 in patients with Post-COVID-19-Syndrome (PC19S) – a randomized controlled trial in primary care | ||
Medical condition: Post-COVID-19-Syndrome (PC19S) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-013400-31 | Sponsor Protocol Number: STEADI-09 | Start Date*: 2010-08-10 |
Sponsor Name:University of Southampton | ||
Full Title: A phase 2, double-blind, placebo-controlled study of the safety and tolerability of etanercept in patients with Alzheimer’s disease | ||
Medical condition: Alzheimer's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003557-15 | Sponsor Protocol Number: HMB-ICU | Start Date*: 2018-08-31 | |||||||||||
Sponsor Name:Guy's and St Thomas NHS Foundation Trust | |||||||||||||
Full Title: A Study to Investigate the Effect of β-Hydroxy-β-Methylbutyrate (HMB) on Skeletal Muscle Wasting in Early Critical Illness. | |||||||||||||
Medical condition: Critical illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000911-25 | Sponsor Protocol Number: BST-LT-01 | Start Date*: 2019-02-12 | |||||||||||
Sponsor Name:Banc de Sang i Teixits | |||||||||||||
Full Title: A prospective multicenter open, not controlled phase Ib-II clinical trial to assess the safety and immunologic efficacy of virus-specific T lymphocytes from the best donor in receptors of hematopoi... | |||||||||||||
Medical condition: CMV viral infection in an immunocompromised host | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005576-18 | Sponsor Protocol Number: CCNP520X2102 | Start Date*: 2015-08-12 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral doses of CNP520 in healthy elderly su... | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) DE (Completed) BE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003651-54 | Sponsor Protocol Number: 2014RISP1 | Start Date*: 2015-10-14 |
Sponsor Name:UMCG | ||
Full Title: ‘Off-label use of Risperidone in Children and Adolescents (ORCA): a double-blind placebo-controlled discontinuation trial’ | ||
Medical condition: no specific condition, we will investigate children who have been using risperidone on an off-label basis for at least one year. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018386-32 | Sponsor Protocol Number: CC-10004-PSA-003 | Start Date*: 2010-12-27 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF TWO DOSES OF APREMILAST (CC-10004) IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS | |||||||||||||
Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6-39% of psoriasis patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) EE (Completed) GB (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) IT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000712-30 | Sponsor Protocol Number: ABR-71432 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Radboudumc | |||||||||||||
Full Title: Targeted glucocorticoid administration to improve safety learning in PTSD patients with HPA axis dysregulation | |||||||||||||
Medical condition: Posttraumatic Stress Disorder (PTSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003214-15 | Sponsor Protocol Number: VP-AD-302 | Start Date*: 2005-12-12 |
Sponsor Name:Voyager Pharmaceutical Corporation | ||
Full Title: A DOUBLE-BLIND PLACEBO- CONTROLLED STUDY OF VP4896 FOR THE TREATMENT OF MILD-TO-MODERATE ALZHEIMER'S DISEASE | ||
Medical condition: | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) LT (Completed) ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-002159-24 | Sponsor Protocol Number: 54861911ALZ2002 | Start Date*: 2014-10-27 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects in the Early (Predementia) Alzheime... | |||||||||||||
Medical condition: Early Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020324-22 | Sponsor Protocol Number: CC-10004-PSA-005 | Start Date*: 2011-03-07 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety study of two doses of Apremilast (CC-10004) in subjects with active psoriatic arthritis who... | |||||||||||||
Medical condition: Psoriatic arthritis, an inflammatory arthritis that occurs in 6 to 39% of patients with psoriasis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) CZ (Completed) LT (Completed) IT (Completed) PL (Completed) BG (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003518-14 | Sponsor Protocol Number: SKY2028-3-003 | Start Date*: 2006-01-25 |
Sponsor Name:Skyepharma AG | ||
Full Title: Long-term Open-label Safety Study with SKP Flutiform HFA pMDI (100/10μg and 250/10μg) in Adult and Adolescent Patients with Asthma | ||
Medical condition: Mild to Moderate-Severe Asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) HU (Completed) DE (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
